ArticleClinical rheumatology2026
Analyzing the expression of hsa-miR-661 in peripheral blood mononuclear cells of patients with primary Sjögren's syndrome and its clinical significance.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to assess the expression and clinical significance of hsa-miR-661 in peripheral blood mononuclear cells (PBMCs) of patients with primary Sjögren's syndrome (pSS) and to explore the role of the hsa_circ_0008301/hsa-miR-661/TOLLIP axis in disease progression.
methodsA total of 58 pSS patients and 58 age- and sex-matched healthy controls, recruited from the General Hospital of Ningxia Medical University between September 2021 and September 2022, were included. Clinical and laboratory data were collected. Hsa-miR-661 expression in PBMCs was measured using quantitative real-time PCR (qRT-PCR). The interaction between hsa_circ_0008301, hsa-miR-661, and TOLLIP was validated using dual-luciferase reporter assays. Group differences were analyzed using t-tests and χ
resultsHsa-miR-661 expression was significantly upregulated in pSS patients compared to controls. Increased levels were associated with longer disease duration, lower C3 and platelet counts, higher ESR, more severe xerostomia, and elevated ESSDAI scores. ROC analysis demonstrated that hsa-miR-661 effectively distinguished pSS patients from healthy individuals and discriminated between high- and low-activity disease states. Functional assays confirmed that hsa_circ_0008301 directly interacts with hsa-miR-661, which targets and regulates TOLLIP.
conclusionHsa-miR-661 is markedly elevated in pSS and closely correlates with disease activity and key clinical indicators. These findings suggest its potential as a diagnostic biomarker and therapeutic target in pSS. Key Points • Hsa-miR-661 is markedly upregulated in peripheral blood mononuclear cells of pSS patients and is closely associated with clinical manifestations and disease activity. • It demonstrates strong diagnostic accuracy (AUC = 0.892) and effectively distinguishes between high and low disease activity (AUC = 0.779). • The circRNA_0008301/miR-661/TOLLIP axis provides mechanistic insight into pSS pathogenesis and highlights a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.